# X Variable Completes Four Consecutive Funding Rounds, Valuation Exceeds 20 Billion Yuan

- Category: Flash (快讯)
- Published: 2026-06-29T11:50:00.000Z
- Source date: 2026-06-29
- HTML: https://www.88z.ai/en/news/flash-20260629-85c095f5039ea651
- Markdown: https://www.88z.ai/en/news/flash-20260629-85c095f5039ea651.md
- Other language: https://www.88z.ai/news/flash-20260629-85c095f5039ea651.md

X Variable completed four consecutive funding rounds within two months, with its post-money valuation exceeding 20 billion yuan, making it the first embodied brain company in the Greater Bay Area to reach this milestone. Meituan, Alibaba, ByteDance, and Xiaomi each led a round, with Xiaomi investing in three consecutive rounds. Over thirty institutions, including 58 Group, Chery, China Mobile, and Sequoia China, participated.

## At a glance

- X Variable completed four funding rounds in two months, valuation exceeds 20 billion yuan
- Meituan, Alibaba, ByteDance, and Xiaomi each led a round; Xiaomi invested in three consecutive rounds

## The update

Embodied intelligence company X Variable has been active in the capital market recently, completing four consecutive funding rounds within just two months. This series of intensive financing activities pushed its post-money valuation past the 20 billion yuan mark, making it the first embodied brain company in the Greater Bay Area to exceed this valuation. The financing attracted more than 30 investors. The four internet giants Meituan, Alibaba, ByteDance, and Xiaomi each led a respective round. Xiaomi was particularly active, adding capital in three consecutive rounds. Additionally, well-known institutions such as 58 Group, Chery Automobile, China Mobile, and Sequoia China all participated to support the company's development.

## Sources

- [量子位](https://mp.weixin.qq.com/s/dsBovOAIJ-3RB7dZLebtIA) (2026-06-29)

This article is an AI-assisted synthesis by 88Z AI based on the public sources below. Product claims and availability are attributed to their publishers. It does not represent independent testing or first-hand reporting.